Meet the team! – Milo Malanga

Some chemists are drawn to elegant molecules but Milo Malanga PhD
is drawn to the difficult ones and cyclodextrins, with all their complexity, are exactly the kind of puzzle he enjoys.

This preference for hard problems also shapes how he sees the work happening around him at CarboHyde. When asked which project he is most proud of, his answer is unexpected, because it is one he barely worked on himself.

“I am most proud of a French partners project, although I have done almost nothing about it. In my opinion, it is the most difficult project at CarboHyde, but it is also the best designed and best executed one – honestly, I could never do a project like this myself.”

There is a rare kind of pride in that answer – the kind that recognizes great work in others and acknowledges the standard a team can reach together.

If Milo could solve just one unanswered question in cyclodextrin chemistry tomorrow, he would not hesitate.

“I would focus on crossing the blood-brain barrier, and on achieving organ-specific tropism through cyclodextrin structure-activity relationships – two challenges that could reshape how active ingredients reach the places they truly need to go.”

The hardest problems rarely come with quick answers, but they are the ones worth showing up for, day after day.:)

BIO International Convention 2026

We are excited to share that CarboHyde will be participating in the BIO International Convention 2026, taking place from June 13 to 16 in San Diego, California.

As one of the largest and most influential gatherings in the global biotech industry, BIO brings together leaders, innovators, and partners from across the value chain. For us at CarboHyde, it is a valuable opportunity to connect with the international community shaping the future of biopharmaceutical research, drug delivery, and advanced chemistry solutions.

We see events like BIO as an important part of building meaningful partnerships and exploring how cyclodextrin-based technologies can support next-generation therapeutic development. Conversations at this level often spark collaborations that lead to real scientific and commercial progress.

If you will also be in San Diego and would like to meet, we would be glad to sit down with you. Please reach out to Tamas Sohajda at tamas.sohajda@carbohyde.com to set up a time.

Looking forward to seeing you there. 🌐

What a proud moment – behold the magic of cyclodextrins!

Our long-time friends and partners at Cyclarity Unveil First-Ever Clinical Data Demonstrating Excretion of Oxidized Cholesterol

Daniel Clemens recently presented the first data from Cyclarity Therapeutics‘ ongoing Phase I trial with UDP-003
Key highligths:

1. Safe excretion of 7KC (7-keto-cholesterol), a core driver of plaque associated with heart disease, stroke, inflammation, and age-related diseases, in humans suggests medicine could move beyond slowing heart disease to disease-modifying plaque reversal

2. First candidate from Cyclarity’s AI Platform reinforces promise of next-generation cyclodextrins to reverse disease and protect against future accumulation of harmful molecules and aging pathologies

Cyclarity’s UDP-003 binds directly to 7KC, the root cause of plaque buildup, then facilitates urinary excretion of it. Much like removing rust from metal, this approach directly targets a key source of damage within plaque with the goal of reversing and preventing atherosclerosis, a primary underlying cause of cardiovascular disease, and does so locally within the plaque to reduce risks of unintended systemic effects.

Plaque reversal is significant because research suggests that even a 1% reduction in coronary plaque burden has been associated with up to 25% lower risk of major cardiovascular events, such as heart attack or stroke.

In parallel, they are preparing for the launch of our Phase 2 trial, expected to kick off in early 2027.

Cyclarity Therapeutics is a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and remove toxic targets to address root causes of age-related disease.

Read the full story here: Cyclarity Unveils First-Ever Clinical Data Demonstrating

Bicyclos HEurope secondment at CarboHyde

When summer approaches, our labs get more colorful, filled with laughter and questions, and students come to learn about cyclodextrins.

Currently, we are hosting two bright guys under the scope of the Bicyclos HEurope project.

Daniele Veclani and Andrea Trifoglio came from Isof CNR (Ilse Manet lab) and work on some new, fancy cyclodextrins – what else?

What exactly? I keep that a secret for now, but I will keep you posted.

This shall be fun again!

I am deeply honored to be invited by PhD Circle (Gjylije Hoti & Visar Vela) to talk about The CarboHyde story

My title is “From Vision to Impact: The Cyclodextrin Revolution at CarboHyde.”

Join us online to discover how innovative applications of cyclodextrins are driving breakthroughs across industries, and how scientific vision can be transformed into real-world impact through entrepreneurship and cutting-edge research.

🗓️ 21 May, 2026
🕖 19:00 CET
📍 Online
🔗https://lnkd.in/da-zSjXH

Don’t miss this opportunity to be a part of the conversation shaping tomorrow’s innovations.

The next masterclass is NOT about cyclodextrins!

Our Indian branch is diving deep into the uses of silicon dioxide and DR NASEEM KHAN will share a lot about its pharma uses and possibilities.

What if one of the most widely used materials in drug formulation is also one of the most promising for the future?

Join us for an insightful webinar exploring the evolving role of silicon dioxide in the pharmaceutical industry. From enhancing drug stability to improving delivery systems, this versatile excipient is shaping the next generation of medicines.

What you’ll learn:
– The functional benefits of silicon dioxide in modern formulations
– Innovations driving its expanded use in pharmaceuticals
– Regulatory considerations and quality standards
– Future trends and research breakthroughs

Silicon Dioxide in Pharmaceuticals – A Future Excipient – CarboHyde

Meet the Team!

Most formulation scientists are drawn to complexity. Balázs Attila Kondoros was drawn to elegance.

“What fascinates me is how cyclodextrins, despite their simple structure, can efficiently encapsulate molecules and solve real formulation challenges.”

Ask him about his proudest achievement, and he does not point to a single project. Instead, he points to a process:

“Rather than one result, I’m most proud of building up the formulation capabilities at CarboHyde together with the team.”

The challenge that keeps him thinking?

“Achieving fully reliable prediction of host–guest interactions. That would significantly accelerate development.”

From molecular elegance to team building to predictive precision, that is how a formulation scientist thinks at CarboHyde.

More stories from the team are coming soon.

Balazs Kondoros

Excited to represent CarboHyde at the DDF Summit in Berlin

Our Lead Formulation Expert, Balázs Attila Kondoros, will be attending the upcoming Drug Delivery & Formulation (DDF) Summit in Berlin, where he’ll be diving into the latest innovations in drug delivery technologies.

At CarboHyde, we are particularly interested in exploring how emerging challenges in formulation and delivery could be addressed using cyclodextrins — unlocking new possibilities for solubility, stability, and bioavailability.

Balazs is looking forward to connecting with fellow experts, exchanging ideas, and identifying collaboration opportunities.

Do you want to learn more about Carbo and cyclodextrins?

Who else will be attending? Let’s connect in Berlin!